Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2011 Aug 16;20(9):1928–1936. doi: 10.1158/1055-9965.EPI-11-0236

Table 3.

Hazard ratios (HR) for prostate cancer-specific mortality associated with the cumulative number of at-risk genotypes for a panel of five validated single nucleotide polymorphisms (SNPs)

Seattle Cohort Swedish Cohort
Number of
at-risk
genotypes1 		Number at-risk
/ Number of
fatal events		 HR2 95% CI HR3 95% CI Number at-risk
/ Number of
fatal events		 HR2 95% CI HR3 95% CI
0 – 2 314 / 4 1.00 1.00 803 / 113 1.00 1.00
3 446 / 16 2.82 0.94–8.45 8.14 2.44–27.12 1047 / 181 1.24 0.98–1.57 1.05 0.81–1.37
4 322 / 16 3.92 1.31–11.74 9.08 2.73–30.15 797 / 154 1.44 1.13–1.83 1.51 1.16–1.97
5 69 / 13 15.80 5.14–48.52 15.12 4.44–51.56 176 / 39 1.69 1.17–2.43 1.46 0.97–2.19
1

Genotypes for SNPs rs1137100, rs627839, rs2070874, rs10778534, and rs5993891; patients missing data for any of the five SNP genotypes were excluded from the analysis (Seattle n=158; Sweden n=52).

2

Hazard ratio adjusted for age at diagnosis; p-value for trend = 0.0005 in the Swedish cohort.

3

Hazard ratio adjusted for age at diagnosis, stage, Gleason score, diagnostic PSA, and primary treatment; p-value for trend = 0.001 in the Swedish cohort.